In short
Efpegerglucagon, also known as HM15136, is being studied in clinical trials as a potential treatment for children aged 2 and older with Congenital Hyperinsulinism (CHI). This rare genetic condition causes excessive insulin production, leading to dangerously low blood sugar levels. The ongoing research aims to evaluate the safety, tolerability, and effectiveness of Efpegerglucagon in managing CHI symptoms and improving patients' quality of life.
At a glance
- Drug Name
- Efpegerglucagon (HM15136)
- Condition Studied
- Congenital Hyperinsulinism (CHI)
- Trial Phase
- Phase 2
- Age Group
- 2 years and older
- Administration
- Subcutaneous injection
- Primary Objectives
- Safety, tolerability, and pharmacokinetics
- Secondary Objectives
- Reduction in hypoglycemia events, long-term safety
- Treatment Duration
- 8 weeks (core period) + 44 weeks (optional extension)
- Key Inclusion Criteria
- CHI diagnosis, ≥3 hypoglycemia events/week, stable on standard therapy
- Key Exclusion Criteria
- Type 1/2 diabetes, serious adverse reactions to study drug, significant lab abnormalities
What is EFPEGERGLUCAGON?
EFPEGERGLUCAGON, also known by its product code HM15136, is a new medication being studied for the treatment of Congenital Hyperinsulinism (CHI) in children aged 2 years and older. It is a solution for injection that comes in a pre-filled syringe and is administered subcutaneously (under the skin).
Understanding Congenital Hyperinsulinism (CHI)
Congenital Hyperinsulinism (CHI) is a rare genetic disorder that affects the body's regulation of blood sugar levels. In CHI, the pancreas produces too much insulin, leading to frequent episodes of low blood sugar (hypoglycemia). This condition can be dangerous, especially for young children, as it can cause seizures, brain damage, and other serious complications if not properly managed.
How EFPEGERGLUCAGON Works
While the exact mechanism of action is not fully described in the provided information, EFPEGERGLUCAGON is likely designed to help regulate blood sugar levels in patients with CHI. It may work by counteracting the effects of excess insulin or by helping to maintain more stable glucose levels in the blood.
Clinical Trial Details
A Phase 2 clinical trial, called ACHIEVE, is being conducted to evaluate EFPEGERGLUCAGON. This trial aims to:
- Assess the safety and tolerability of EFPEGERGLUCAGON
- Study how the drug is processed in the body (pharmacokinetics)
- Evaluate its effectiveness in reducing hypoglycemic events
The trial consists of an 8-week core treatment period, followed by an optional 44-week extension period for long-term evaluation.
Eligibility Criteria
To participate in the EFPEGERGLUCAGON trial, patients must meet certain criteria, including:
- Be at least 2 years old
- Have a confirmed diagnosis of CHI
- Experience at least 3 hypoglycemic events per week (blood glucose <70 mg/dL or <3.9 mmol/L)
- Be on stable therapy with current standard-of-care medications or have documented non-response to these treatments
There are also several exclusion criteria, such as having type 1 or type 2 diabetes, severe anemia, or certain other medical conditions.
Safety and Side Effects
As this is an ongoing clinical trial, the full safety profile of EFPEGERGLUCAGON is not yet known. The study is closely monitoring for any adverse events (side effects) that may occur during treatment. Some areas being evaluated include:
- Changes in laboratory test results
- Effects on vital signs (blood pressure, heart rate, etc.)
- Changes in ECG parameters, particularly the QT interval
- Immune system responses to the medication
Patients and caregivers should report any unusual symptoms or side effects to their healthcare providers immediately.
Potential Benefits
If successful, EFPEGERGLUCAGON could offer several potential benefits for patients with CHI:
- Reduction in the frequency and severity of hypoglycemic events
- Improved quality of life for patients and their families
- Potentially fewer complications associated with chronic low blood sugar
- A new treatment option for patients who don't respond well to current therapies
It's important to note that as EFPEGERGLUCAGON is still in clinical trials, its effectiveness and long-term benefits are yet to be fully determined.